Raymond James Financial Services Advisors’s Niagen Bioscience NAGE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-87,029	Closed	-$349K	–	3100
2020 Q3	$349K	Buy	87,029 +400	+0.5%	+$1.93K	﹤0.01%	2201
2020 Q2	$398K	Sell	86,629 -1,925	-2%	-$8.62K	﹤0.01%	2063
2020 Q1	$289K	Sell	88,554 -9,070	-9%	-$34.8K	﹤0.01%	1868
2019 Q4	$421K	Hold	97,624	–	–	﹤0.01%	2090
2019 Q3	$384K	Buy	+97,624	New	+$416K	﹤0.01%	2074
2017 Q3	–	Sell	-10,334	Closed	-$39K	–	2638
2017 Q2	$39K	Buy	+10,334	New	+$32.7K	﹤0.01%	2429

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial Services Advisors's NAGE Position: Q4 2020 in Review

Raymond James Financial Services Advisors sold out of Niagen Bioscience (NAGE) in Q4 2020, closing a stake of 87,029 shares — an estimated $349K sold.

Raymond James Financial Services Advisors first reported a position in NAGE in Q2 2017 and held it in 6 quarters. The position peaked at $421K in Q4 2019. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2020.

Raymond James Financial Services Advisors reported no remaining Niagen Bioscience position as of Q4 2020 after selling out during the quarter.
Raymond James Financial Services Advisors sold 87,029 Niagen Bioscience shares in Q4 2020, an estimated $349K.
Raymond James Financial Services Advisors first reported a position in Niagen Bioscience in Q2 2017 and held it in 6 quarters.
Raymond James Financial Services Advisors's Niagen Bioscience position peaked at $421K in Q4 2019.
83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.